J
Junliang Cai
Researcher at Bristol-Myers Squibb
Publications - 2
Citations - 168
Junliang Cai is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: non-small cell lung cancer (NSCLC) & Nivolumab. The author has an hindex of 2, co-authored 2 publications receiving 27 citations.
Papers
More filters
Journal ArticleDOI
Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).
Jonathan Spicer,Changli Wang,Fumihiro Tanaka,Gene Brian Saylors,Ke-Neng Chen,Moishe Liberman,Everett E. Vokes,Nicolas Girard,Shun Lu,Mariano Provencio,Tetsuya Mitsudomi,Mark M. Awad,Enriqueta Felip,Patrick M. Forde,Scott J. Swanson,Julie R. Brahmer,Keith M. Kerr,Cecile Dorange,Junliang Cai,Stephen Broderick +19 more
TL;DR: The study met its first primary endpoint, demonstrating significa… CheckMate 816 (NCT02998528) meets its firstPrimary endpoint.
Proceedings ArticleDOI
Abstract CT003: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial
Patrick M. Forde,Jonathan Spicer,Shun Lu,Mariano Provencio,Tetsuya Mitsudomi,Mark M. Awad,Enriqueta Felip,Stephen Broderick,Julie R. Brahmer,Scott J. Swanson,Keith M. Kerr,Changli Wang,Gene B. Saylors,Fumihiro Tanaka,Hiroyuki Ito,Ke-Neng Chen,Cecile Dorange,Junliang Cai,Joseph Fiore,Nicholas Girard +19 more
TL;DR: CheckMate 816 is the first positive phase 3 trial demonstrating a significant improvement in pathologic response with neoadjuvant immunotherapy plus chemo in resectable NSCLC and the safety profile of NIVO + chemo was consistent with the known profile of this combination regimen.